LMR Partners’s 4D Molecular Therapeutics FDMT Stock Holding History

LMR Partners’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-487,533	Closed	-$15.5M	–	1165
2024 Q1	$15.5M	Buy	+487,533	New	+$12.4M	0.16%	134

Other funds holding FDMT

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LMR Partners's FDMT Position: Q2 2024 in Review

LMR Partners sold out of 4D Molecular Therapeutics (FDMT) in Q2 2024, closing a stake of 487,533 shares — an estimated $15.5M sold.

LMR Partners first reported a position in FDMT in Q1 2024 and held it in 1 quarter. The position peaked at $15.5M in Q1 2024. 143 funds tracked by Wall St. Rank hold FDMT as of Q2 2024.

LMR Partners reported no remaining 4D Molecular Therapeutics position as of Q2 2024 after selling out during the quarter.
LMR Partners sold 487,533 4D Molecular Therapeutics shares in Q2 2024, an estimated $15.5M.
LMR Partners first reported a position in 4D Molecular Therapeutics in Q1 2024 and held it in 1 quarter.
LMR Partners's 4D Molecular Therapeutics position peaked at $15.5M in Q1 2024.
143 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2024.

Based on LMR Partners's 13F filing for Q2 2024, filed 14 Aug 2024.